AstraZeneca

Activities: Drug Delivery Research & Development Pharmaceutical

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  2. IDT opens molecular biology research facility in Redwood City Dr Caifu Chen to lead new product development at California site
  3. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity
  5. Discover a new standard in self-priming pump technology Alfa Laval offers hygienic pumping with more efficiency and less noise

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Pharmaceutical

AstraZeneca appoints Iskra Reic as its International Executive Vice President

Iskra will be responsible for championing AstraZeneca's growth across key markets globally, as well as business strategy development
Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC
Manufacturing

AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities

The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical research and development capabilities through this investment
Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Regulatory

AstraZeneca's Wainzua recommended for EU approval to treat amyloidosis

The neuropathy drug was developed in tandem with Ionis, and has been shown to reduce neuropathy and increase quality of life in the Phase III NEURO-TTransform trial
Research & Development

AstraZeneca's asthma-targeting Airsupra meets primary endpoint in Phase III trial

The inhaled therapeutic has proven effective in reducing the risk of severe asthma attacks in patients with intermittent or persistent asthma
Subscribe now